User:Mr. Ibrahem/Pegloticase

Pegloticase, sold under the brand name Krystexxa, is a medication used to treat chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. It is given by injection into a vein.

Common side effects include worsening gout, pain at the site of injection, nausea, bruising, constipation, and anaphylaxis. Other side effects may include worsening heart failure. It should not be used in people with G6PD deficiency. It is a manufactured form of the enzyme urate oxidase (uricase).

Pegloticase was approved for medical use in the United States in 2010. It was approved in 2013 in Europe but this was withdrawn in 2016. In the United States it costs about 26,000 USD per dose.